Atika Capital Management LLC Otonomy, Inc. Transaction History

Atika Capital Management LLC

  • $841 Million
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2017

Nov 14, 2017
SELL
$3.2 - $20.8 $268,800 - $1.75 Million
-84,000 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
84,000
84,000 $1.58 Million

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Atika Capital Management LLC Portfolio

Follow Atika Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atika Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email